Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00527917
Status:
COMPLETED
Last Update Posted:
2009-12-09
First Post:
2007-09-07
Brief Title:
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst Versus Placebo in Patients With Interstitial CystitisPainful Bladder Syndrome
Sponsor:
Watson Pharmaceuticals
Organization:
Watson Pharmaceuticals
Study Overview
Official Title:
A Multi-Center Randomized Double-Blind Parallel Group Evaluation of the Efficacy and Safety of Uracyst Intravesical Sodium Chondroitin Sulfate Versus Vehicle Placebo in Patients With Interstitial CystitisPainful Bladder Syndrome
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a pilot clinical investigation Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive either an active product Uracyst or placebo intravesically via a bladder catheter weekly for 6 weeks followed by 6 weeks of follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None